A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

Role of cyclin-dependent kinase inhibitors

Ana A. Tula-Sanchez, Aaron P. Havas, Peter J. Alonge, Mary E. Klein, Samantha R. Doctor, William Pinkston, Betty J. Glinsmann-Gibson, Lisa M Rimsza, Catharine Smith

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors (HDAC i) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. However, most patients showed no response to HDAC i monotherapy for unknown reasons. Here we show that sensitivity and resistance to the hydroxamate HDAC i, PXD101, can be modeled in DLBCL cell lines. Sensitivity is characterized by G2/M arrest and apoptosis and resistance by reversible G1 growth arrest. These responses to PXD101 are independent of several negative prognostic indicators such as DLBCL subtype, BCL2 and MYC co-expression, and p53 mutation, suggesting that HDAC i might be used effectively against highly aggressive DLBCL tumors if they are combined with other therapeutics that overcome HDAC i resistance. Our investigation of mechanisms underlying HDAC i resistance showed that cyclin-dependent kinase inhibitors (CKIs), p21 and p27, are upregulated by PXD101 in a sustained fashion in resistant cell lines concomitant with decreased activity of the cyclin E/cdk2 complex and decreased Rb phosphorylation. PXD101 treatment results in increased association of CKI with the cyclin E/cdk2 complex in resistant cell lines but not in a sensitive line, indicating that the CKIs play a key role in G1 arrest. The results suggest several treatment strategies that might increase the efficacy of HDAC i against aggressive DLBCL.

Original languageEnglish (US)
Pages (from-to)949-961
Number of pages13
JournalCancer Biology and Therapy
Volume14
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

Histone Deacetylase Inhibitors
Cyclin-Dependent Kinases
Lymphoma, Large B-Cell, Diffuse
Cyclin E
Cell Line
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
Therapeutics
Non-Hodgkin's Lymphoma
Neoplasms
Phosphorylation
Apoptosis
Recurrence
Mutation
belinostat
Growth
Pharmaceutical Preparations

Keywords

  • BCL2
  • Cell cycle
  • Cell cycle inhibitors
  • Drug resistance
  • Histone deacetylase inhibitor
  • Lymphoma
  • MYC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma : Role of cyclin-dependent kinase inhibitors. / Tula-Sanchez, Ana A.; Havas, Aaron P.; Alonge, Peter J.; Klein, Mary E.; Doctor, Samantha R.; Pinkston, William; Glinsmann-Gibson, Betty J.; Rimsza, Lisa M; Smith, Catharine.

In: Cancer Biology and Therapy, Vol. 14, No. 10, 10.2013, p. 949-961.

Research output: Contribution to journalArticle

Tula-Sanchez, Ana A. ; Havas, Aaron P. ; Alonge, Peter J. ; Klein, Mary E. ; Doctor, Samantha R. ; Pinkston, William ; Glinsmann-Gibson, Betty J. ; Rimsza, Lisa M ; Smith, Catharine. / A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma : Role of cyclin-dependent kinase inhibitors. In: Cancer Biology and Therapy. 2013 ; Vol. 14, No. 10. pp. 949-961.
@article{7252f7875aad44baa4a55ece0ff3c059,
title = "A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors",
abstract = "Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40{\%} of cases. Histone deacetylase inhibitors (HDAC i) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. However, most patients showed no response to HDAC i monotherapy for unknown reasons. Here we show that sensitivity and resistance to the hydroxamate HDAC i, PXD101, can be modeled in DLBCL cell lines. Sensitivity is characterized by G2/M arrest and apoptosis and resistance by reversible G1 growth arrest. These responses to PXD101 are independent of several negative prognostic indicators such as DLBCL subtype, BCL2 and MYC co-expression, and p53 mutation, suggesting that HDAC i might be used effectively against highly aggressive DLBCL tumors if they are combined with other therapeutics that overcome HDAC i resistance. Our investigation of mechanisms underlying HDAC i resistance showed that cyclin-dependent kinase inhibitors (CKIs), p21 and p27, are upregulated by PXD101 in a sustained fashion in resistant cell lines concomitant with decreased activity of the cyclin E/cdk2 complex and decreased Rb phosphorylation. PXD101 treatment results in increased association of CKI with the cyclin E/cdk2 complex in resistant cell lines but not in a sensitive line, indicating that the CKIs play a key role in G1 arrest. The results suggest several treatment strategies that might increase the efficacy of HDAC i against aggressive DLBCL.",
keywords = "BCL2, Cell cycle, Cell cycle inhibitors, Drug resistance, Histone deacetylase inhibitor, Lymphoma, MYC",
author = "Tula-Sanchez, {Ana A.} and Havas, {Aaron P.} and Alonge, {Peter J.} and Klein, {Mary E.} and Doctor, {Samantha R.} and William Pinkston and Glinsmann-Gibson, {Betty J.} and Rimsza, {Lisa M} and Catharine Smith",
year = "2013",
month = "10",
doi = "10.4161/cbt.25941",
language = "English (US)",
volume = "14",
pages = "949--961",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma

T2 - Role of cyclin-dependent kinase inhibitors

AU - Tula-Sanchez, Ana A.

AU - Havas, Aaron P.

AU - Alonge, Peter J.

AU - Klein, Mary E.

AU - Doctor, Samantha R.

AU - Pinkston, William

AU - Glinsmann-Gibson, Betty J.

AU - Rimsza, Lisa M

AU - Smith, Catharine

PY - 2013/10

Y1 - 2013/10

N2 - Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors (HDAC i) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. However, most patients showed no response to HDAC i monotherapy for unknown reasons. Here we show that sensitivity and resistance to the hydroxamate HDAC i, PXD101, can be modeled in DLBCL cell lines. Sensitivity is characterized by G2/M arrest and apoptosis and resistance by reversible G1 growth arrest. These responses to PXD101 are independent of several negative prognostic indicators such as DLBCL subtype, BCL2 and MYC co-expression, and p53 mutation, suggesting that HDAC i might be used effectively against highly aggressive DLBCL tumors if they are combined with other therapeutics that overcome HDAC i resistance. Our investigation of mechanisms underlying HDAC i resistance showed that cyclin-dependent kinase inhibitors (CKIs), p21 and p27, are upregulated by PXD101 in a sustained fashion in resistant cell lines concomitant with decreased activity of the cyclin E/cdk2 complex and decreased Rb phosphorylation. PXD101 treatment results in increased association of CKI with the cyclin E/cdk2 complex in resistant cell lines but not in a sensitive line, indicating that the CKIs play a key role in G1 arrest. The results suggest several treatment strategies that might increase the efficacy of HDAC i against aggressive DLBCL.

AB - Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors (HDAC i) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. However, most patients showed no response to HDAC i monotherapy for unknown reasons. Here we show that sensitivity and resistance to the hydroxamate HDAC i, PXD101, can be modeled in DLBCL cell lines. Sensitivity is characterized by G2/M arrest and apoptosis and resistance by reversible G1 growth arrest. These responses to PXD101 are independent of several negative prognostic indicators such as DLBCL subtype, BCL2 and MYC co-expression, and p53 mutation, suggesting that HDAC i might be used effectively against highly aggressive DLBCL tumors if they are combined with other therapeutics that overcome HDAC i resistance. Our investigation of mechanisms underlying HDAC i resistance showed that cyclin-dependent kinase inhibitors (CKIs), p21 and p27, are upregulated by PXD101 in a sustained fashion in resistant cell lines concomitant with decreased activity of the cyclin E/cdk2 complex and decreased Rb phosphorylation. PXD101 treatment results in increased association of CKI with the cyclin E/cdk2 complex in resistant cell lines but not in a sensitive line, indicating that the CKIs play a key role in G1 arrest. The results suggest several treatment strategies that might increase the efficacy of HDAC i against aggressive DLBCL.

KW - BCL2

KW - Cell cycle

KW - Cell cycle inhibitors

KW - Drug resistance

KW - Histone deacetylase inhibitor

KW - Lymphoma

KW - MYC

UR - http://www.scopus.com/inward/record.url?scp=84885224051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885224051&partnerID=8YFLogxK

U2 - 10.4161/cbt.25941

DO - 10.4161/cbt.25941

M3 - Article

VL - 14

SP - 949

EP - 961

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -